<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01831466</url>
  </required_header>
  <id_info>
    <org_study_id>A3921082</org_study_id>
    <secondary_id>2012-005645-20</secondary_id>
    <nct_id>NCT01831466</nct_id>
  </id_info>
  <brief_title>Tofacitinib Ointment For Chronic Plaque Psoriasis</brief_title>
  <official_title>A Phase 2b, Multi-site, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study Of The Efficacy, Safety, Local Tolerability And Pharmacokinetics Of 2 Dose Strengths And 2 Regimens Of Tofacitinib Ointment In Subjects With Chronic Plaque Psoriasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is beng done to test if tofacitinib ointment is safe and effective for people with
      plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied
      once or twice daily are being tested. The safety and effectiveness of tofacitinib ointment
      used for 12 weeks will be compared to the safety and effectiveness of placebo ointment
      (vehicle) used for 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Clinical signs of plaque psoriasis (erythema [E], induration [I], and scaling [S]) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Gestalt Physician's Global Assessment (PGA-G) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a PGA-G Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Psoriasis Area and Severity Index (PASI)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent (%) area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region*area score*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was &lt;72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 8 in PASI</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region*area score*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was &lt;72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving at Least a 75% Reduction in PASI Response (PASI75), Relative to Baseline at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region*area score*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was &lt;72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PASI75, Relative to Baseline at Week 8</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region*area score*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was &lt;72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 12 in Body Surface Area (BSA) Affected With Psoriasis</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Week 8 in BSA Affected With Psoriasis</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Clinic-Based Itch Severity Item (ISI) Scores</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their &quot;worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;no itching&quot; (0) and &quot;worst possible itching&quot; (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Clinic-Based ISI Scores</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their &quot;worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;no itching&quot; (0) and &quot;worst possible itching&quot; (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in the Dermatology Life Quality Index (DLQI) Total Score</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in the DLQI Total Score</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Patient's Global Assessment (PtGA) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12 for Participants With a PtGA Score ≥2 at Baseline</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a PtGA Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8 for Participants With a PtGA Score ≥2 at Baseline</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">476</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group F</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib ointment 20 mg/g</intervention_name>
    <description>tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks</description>
    <arm_group_label>Treatment Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib ointment 10 mg/g</intervention_name>
    <description>tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks</description>
    <arm_group_label>Treatment Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo ointment (vehicle)</intervention_name>
    <description>placebo ointment (vehicle) BID (twice daily) for 12 weeks</description>
    <arm_group_label>Treatment Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib ointment 20 mg/g</intervention_name>
    <description>tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks</description>
    <arm_group_label>Treatment Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tofacitinib ointment 10 mg/g</intervention_name>
    <description>tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks</description>
    <arm_group_label>Treatment Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo ointment (vehicle)</intervention_name>
    <description>placebo ointment (vehicle) QD (once daily) for 12 weeks</description>
    <arm_group_label>Treatment Group F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have mild, moderate or severe plaque psoriasis (psoriasis vulgaris) for at least 6
             months prior to Baseline

          -  At Baseline, have plaque psoriasis covering 2% to 20% of total body surface area (BSA)
             on the trunk and limbs (excluding palms, soles, and nails)

          -  If received certain treatments, should be off treatment for a minimum period of time
             (washout)

        Exclusion Criteria:

          -  Currently have non-plaque forms of psoriasis or drug-induced psoriasis

          -  Require treatment with or cannot stop medication(s) prohibited during the study

          -  Have certain laboratory abnormalities at Baseline

          -  Current or history of certain infections

          -  Females who are pregnant, breastfeeding, or are of childbearing potential not using
             highly effective contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bakersfield Dermatology and Skin Cancer Medical Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Irvine Dermatology Research</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Avenue Dermatology, PA</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Dermatology, Vein &amp; Research Center</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research, Inc</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedaPhase Inc.</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dundee Dermatology</name>
      <address>
        <city>West Dundee</city>
        <state>Illinois</state>
        <zip>60118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Center for Skin Care Research</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Inc.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Research Center Inc.</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Treatment and Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Menter Dermatology Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce and Associates, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lee Medical Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stratica Medical</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermadvances Research</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 1R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCA Medical Research Corporation</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultranova Skincare</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatrials Research</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Guenther Dermatology Research Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKiN Centre for Dermatology</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XLR8 Medical Research</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siena Medical Research</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologisk Afdeling S</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudklinikken Herning</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Ambroziak ESTEDERM Sp. z o.o.SKA</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-758</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Solumed</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-539</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zdrowie Osteo-Medic s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Osteoporozy i Chorob Kostno-Stawowych J. Badurski Spolka Jawna</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pomorskie Centrum Traumatologii im.Mikolaja Kopernika w Gdansku Oddzial Dermatologii</name>
      <address>
        <city>Gdansk</city>
        <zip>80-152</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowskie Centrum Medyczne Sp. z o.o.</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxxmed Centrum Zdrowia i Urody</name>
      <address>
        <city>Lublin</city>
        <zip>20-080</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Lekarski RTG USG Dr n. med. Pawel Skrzywanek; Pracownia Radiologiczna</name>
      <address>
        <city>Poznan</city>
        <zip>61-841</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny</name>
      <address>
        <city>Warszawa 44</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>High-Med. Przychodnia Specjalistyczna</name>
      <address>
        <city>Warszawa</city>
        <zip>01-817</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ multiMedica</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-318</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921082&amp;StudyName=Tofacitinib%20Ointment%20For%20Chronic%20Plaque%20Psoriasis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2013</study_first_submitted>
  <study_first_submitted_qc>April 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2013</study_first_posted>
  <results_first_submitted>September 15, 2015</results_first_submitted>
  <results_first_submitted_qc>October 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2015</results_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plaque psoriasis</keyword>
  <keyword>vulgaris</keyword>
  <keyword>topical treatment</keyword>
  <keyword>skin diseases</keyword>
  <keyword>papulosquamous</keyword>
  <keyword>Tofacitinib</keyword>
  <keyword>CP-690550</keyword>
  <keyword>Xeljanz</keyword>
  <keyword>psoriasis</keyword>
  <keyword>moderate</keyword>
  <keyword>severe</keyword>
  <keyword>itch</keyword>
  <keyword>nail psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with mild (PGA-C score of 2), moderate (PGA-C score of 3), or severe (PGA-C score of 4) chronic plaque psoriasis were recruited for this study. The primary analysis population for this study included only the participants with mild and moderate disease.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Mild/Moderate: Tofacitinib 20 mg/Gram (mg/g) Twice Daily (BID)</title>
          <description>Participants with a baseline Calculated Physician’s Global Assessment (PGA-C) score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Mild/Moderate: Placebo (Vehicle) BID</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Mild/Moderate: Tofacitinib 20 mg/g Once Daily (QD)</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Mild/Moderate: Placebo (Vehicle) QD</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Severe: Tofacitinib 20 mg/g BID</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Severe: Tofacitinib 10 mg/g BID</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
        </group>
        <group group_id="P9">
          <title>Severe: Placebo (Vehicle) BID</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied placebo ointment (vehicle), BID for 12 weeks.</description>
        </group>
        <group group_id="P10">
          <title>Severe: Tofacitinib 20 mg/g QD</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
        </group>
        <group group_id="P11">
          <title>Severe: Tofacitinib 10 mg/g QD</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
        </group>
        <group group_id="P12">
          <title>Severe: Placebo (Vehicle) QD</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied placebo ointment (vehicle), QD for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71">Treated</participants>
                <participants group_id="P2" count="70">Treated</participants>
                <participants group_id="P3" count="71">Treated</participants>
                <participants group_id="P4" count="70">Treated</participants>
                <participants group_id="P5" count="74">Treated</participants>
                <participants group_id="P6" count="74">Treated</participants>
                <participants group_id="P7" count="7">Treated</participants>
                <participants group_id="P8" count="7">Treated</participants>
                <participants group_id="P9" count="7">Treated</participants>
                <participants group_id="P10" count="7">Treated</participants>
                <participants group_id="P11" count="6">Treated</participants>
                <participants group_id="P12" count="7">Treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="57"/>
                <participants group_id="P6" count="48"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="4"/>
                <participants group_id="P12" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="26"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="5"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS) - included all participants who were randomized to the study, received at least one dose of the randomized investigational drug (tofacitinib or vehicle), and were in a baseline PGA-C category of mild (2), moderate (3) or severe (4).</population>
      <group_list>
        <group group_id="B1">
          <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Mild/Moderate: Placebo (Vehicle) BID</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Mild/Moderate: Placebo (Vehicle) QD</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Severe: Tofacitinib 20 mg/g BID</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Severe: Tofacitinib 10 mg/g BID</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
        </group>
        <group group_id="B9">
          <title>Severe: Placebo (Vehicle) BID</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied placebo ointment (vehicle), BID for 12 weeks.</description>
        </group>
        <group group_id="B10">
          <title>Severe: Tofacitinib 20 mg/g QD</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
        </group>
        <group group_id="B11">
          <title>Severe: Tofacitinib 10 mg/g QD</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
        </group>
        <group group_id="B12">
          <title>Severe: Placebo (Vehicle) QD</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied placebo ointment (vehicle), QD for 12 weeks.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="71"/>
            <count group_id="B4" value="70"/>
            <count group_id="B5" value="74"/>
            <count group_id="B6" value="74"/>
            <count group_id="B7" value="7"/>
            <count group_id="B8" value="7"/>
            <count group_id="B9" value="7"/>
            <count group_id="B10" value="7"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="7"/>
            <count group_id="B13" value="471"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18-44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45-64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week 12</title>
        <description>Clinical signs of plaque psoriasis (erythema [E], induration [I], and scaling [S]) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The mild/moderate full analysis set (FASm) included all participants in the FAS with a baseline PGA-C disease severity of mild (2) or moderate (3). A participant with a missing value was considered a non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week 12</title>
          <description>Clinical signs of plaque psoriasis (erythema [E], induration [I], and scaling [S]) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.</description>
          <population>The mild/moderate full analysis set (FASm) included all participants in the FAS with a baseline PGA-C disease severity of mild (2) or moderate (3). A participant with a missing value was considered a non-responder.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1"/>
                    <measurement group_id="O2" value="12.9"/>
                    <measurement group_id="O3" value="16.9"/>
                    <measurement group_id="O4" value="20.0"/>
                    <measurement group_id="O5" value="21.6"/>
                    <measurement group_id="O6" value="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5425</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in response rates</param_type>
            <param_value>3.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.36</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>12.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4976</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in response rates</param_type>
            <param_value>-4.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.87</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.5</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6039</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in response rates</param_type>
            <param_value>3.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.36</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.9</ci_lower_limit>
            <ci_upper_limit>11.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5279</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in response rate</param_type>
            <param_value>4.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.34</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>12.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8</title>
        <description>Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FASm. A participant with a missing value was considered a non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8</title>
          <description>Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.</description>
          <population>FASm. A participant with a missing value was considered a non-responder.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5"/>
                    <measurement group_id="O2" value="10.0"/>
                    <measurement group_id="O3" value="11.3"/>
                    <measurement group_id="O4" value="18.6"/>
                    <measurement group_id="O5" value="14.9"/>
                    <measurement group_id="O6" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0710</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in response rates</param_type>
            <param_value>10.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.99</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.1</ci_lower_limit>
            <ci_upper_limit>18.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8175</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in response rates</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.20</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.9</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0513</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in response rates</param_type>
            <param_value>11.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.63</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.8</ci_lower_limit>
            <ci_upper_limit>18.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2021</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in response rates</param_type>
            <param_value>6.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>5.23</dispersion_value>
            <ci_percent>80</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>13.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 12</title>
        <description>Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.</description>
        <time_frame>Week 12</time_frame>
        <population>FASm. A participant with a missing value was considered a non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 12</title>
          <description>Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.</description>
          <population>FASm. A participant with a missing value was considered a non-responder.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8"/>
                    <measurement group_id="O2" value="25.7"/>
                    <measurement group_id="O3" value="23.9"/>
                    <measurement group_id="O4" value="27.1"/>
                    <measurement group_id="O5" value="29.7"/>
                    <measurement group_id="O6" value="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 8</title>
        <description>Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.</description>
        <time_frame>Week 8</time_frame>
        <population>FASm. A participant with a missing value was considered a non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 8</title>
          <description>Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.</description>
          <population>FASm. A participant with a missing value was considered a non-responder.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="22.5"/>
                    <measurement group_id="O4" value="32.9"/>
                    <measurement group_id="O5" value="21.6"/>
                    <measurement group_id="O6" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Gestalt Physician's Global Assessment (PGA-G) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12</title>
        <description>Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FASm. A participant with a missing value was considered a non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Gestalt Physician's Global Assessment (PGA-G) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12</title>
          <description>Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.</description>
          <population>FASm. A participant with a missing value was considered a non-responder.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3"/>
                    <measurement group_id="O2" value="11.4"/>
                    <measurement group_id="O3" value="14.1"/>
                    <measurement group_id="O4" value="15.7"/>
                    <measurement group_id="O5" value="18.9"/>
                    <measurement group_id="O6" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a PGA-G Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8</title>
        <description>Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FASm. A participant with a missing value was considered a non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a PGA-G Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8</title>
          <description>Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.</description>
          <population>FASm. A participant with a missing value was considered a non-responder.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="11.3"/>
                    <measurement group_id="O4" value="15.7"/>
                    <measurement group_id="O5" value="9.5"/>
                    <measurement group_id="O6" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Psoriasis Area and Severity Index (PASI)</title>
        <description>Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent (%) area of skin involved was estimated: 0=0% to 6=90–100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region*area score*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was &lt;72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FASm. Only observed data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Psoriasis Area and Severity Index (PASI)</title>
          <description>Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent (%) area of skin involved was estimated: 0=0% to 6=90–100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region*area score*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was &lt;72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.</description>
          <population>FASm. Only observed data were analyzed.</population>
          <units>Percent Change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="62"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.6" spread="40.88"/>
                    <measurement group_id="O2" value="-35.7" spread="43.78"/>
                    <measurement group_id="O3" value="-32.0" spread="49.47"/>
                    <measurement group_id="O4" value="-38.6" spread="36.37"/>
                    <measurement group_id="O5" value="-31.4" spread="42.36"/>
                    <measurement group_id="O6" value="-30.0" spread="38.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 8 in PASI</title>
        <description>Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region*area score*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was &lt;72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FASm. Only observed data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 8 in PASI</title>
          <description>Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region*area score*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was &lt;72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.</description>
          <population>FASm. Only observed data were analyzed.</population>
          <units>Percent Change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.7" spread="36.01"/>
                    <measurement group_id="O2" value="-29.1" spread="40.86"/>
                    <measurement group_id="O3" value="-28.8" spread="37.06"/>
                    <measurement group_id="O4" value="-36.5" spread="33.87"/>
                    <measurement group_id="O5" value="-29.0" spread="29.47"/>
                    <measurement group_id="O6" value="-27.1" spread="32.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving at Least a 75% Reduction in PASI Response (PASI75), Relative to Baseline at Week 12</title>
        <description>Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region*area score*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was &lt;72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FASm. A participant with a missing value was considered a non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving at Least a 75% Reduction in PASI Response (PASI75), Relative to Baseline at Week 12</title>
          <description>Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region*area score*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was &lt;72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.</description>
          <population>FASm. A participant with a missing value was considered a non-responder.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9"/>
                    <measurement group_id="O2" value="12.9"/>
                    <measurement group_id="O3" value="12.7"/>
                    <measurement group_id="O4" value="15.7"/>
                    <measurement group_id="O5" value="10.8"/>
                    <measurement group_id="O6" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PASI75, Relative to Baseline at Week 8</title>
        <description>Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region*area score*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was &lt;72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FASm. A participant with a missing value was considered a non-responder.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving PASI75, Relative to Baseline at Week 8</title>
          <description>Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region*area score*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was &lt;72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.</description>
          <population>FASm. A participant with a missing value was considered a non-responder.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="70"/>
                <count group_id="O5" value="74"/>
                <count group_id="O6" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1"/>
                    <measurement group_id="O2" value="8.6"/>
                    <measurement group_id="O3" value="7.0"/>
                    <measurement group_id="O4" value="15.7"/>
                    <measurement group_id="O5" value="6.8"/>
                    <measurement group_id="O6" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 12 in Body Surface Area (BSA) Affected With Psoriasis</title>
        <description>Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FASm. Only observed data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 12 in Body Surface Area (BSA) Affected With Psoriasis</title>
          <description>Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.</description>
          <population>FASm. Only observed data were analyzed.</population>
          <units>Percent Change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="62"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.8" spread="40.92"/>
                    <measurement group_id="O2" value="-27.5" spread="36.40"/>
                    <measurement group_id="O3" value="-27.7" spread="43.43"/>
                    <measurement group_id="O4" value="-24.6" spread="36.29"/>
                    <measurement group_id="O5" value="-15.6" spread="36.63"/>
                    <measurement group_id="O6" value="-11.2" spread="56.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Week 8 in BSA Affected With Psoriasis</title>
        <description>Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FASm. Only observed data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Week 8 in BSA Affected With Psoriasis</title>
          <description>Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.</description>
          <population>FASm. Only observed data were analyzed.</population>
          <units>Percent Change from Baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.4" spread="44.75"/>
                    <measurement group_id="O2" value="-22.5" spread="35.87"/>
                    <measurement group_id="O3" value="-20.5" spread="34.90"/>
                    <measurement group_id="O4" value="-17.8" spread="28.59"/>
                    <measurement group_id="O5" value="-9.0" spread="30.08"/>
                    <measurement group_id="O6" value="-11.7" spread="38.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Clinic-Based Itch Severity Item (ISI) Scores</title>
        <description>The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their “worst itching due to psoriasis over the past 24 hours” on a numeric rating scale anchored by the terms “no itching” (0) and “worst possible itching” (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FASm. Only observed data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Clinic-Based Itch Severity Item (ISI) Scores</title>
          <description>The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their “worst itching due to psoriasis over the past 24 hours” on a numeric rating scale anchored by the terms “no itching” (0) and “worst possible itching” (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).</description>
          <population>FASm. Only observed data were analyzed.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="62"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.88" spread="3.140"/>
                    <measurement group_id="O2" value="-2.89" spread="3.320"/>
                    <measurement group_id="O3" value="-1.73" spread="2.460"/>
                    <measurement group_id="O4" value="-2.38" spread="3.182"/>
                    <measurement group_id="O5" value="-1.94" spread="3.151"/>
                    <measurement group_id="O6" value="-1.50" spread="2.961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Clinic-Based ISI Scores</title>
        <description>The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their “worst itching due to psoriasis over the past 24 hours” on a numeric rating scale anchored by the terms “no itching” (0) and “worst possible itching” (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FASm. Only observed data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Clinic-Based ISI Scores</title>
          <description>The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their “worst itching due to psoriasis over the past 24 hours” on a numeric rating scale anchored by the terms “no itching” (0) and “worst possible itching” (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).</description>
          <population>FASm. Only observed data were analyzed.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="59"/>
                <count group_id="O5" value="66"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.07" spread="2.971"/>
                    <measurement group_id="O2" value="-2.38" spread="2.984"/>
                    <measurement group_id="O3" value="-1.45" spread="2.847"/>
                    <measurement group_id="O4" value="-2.49" spread="2.769"/>
                    <measurement group_id="O5" value="-1.91" spread="3.166"/>
                    <measurement group_id="O6" value="-1.34" spread="3.285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in the Dermatology Life Quality Index (DLQI) Total Score</title>
        <description>DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FASm. Only observed data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in the Dermatology Life Quality Index (DLQI) Total Score</title>
          <description>DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
          <population>FASm. Only observed data were analyzed.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="62"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="5.55"/>
                    <measurement group_id="O2" value="-3.2" spread="5.32"/>
                    <measurement group_id="O3" value="-2.6" spread="5.45"/>
                    <measurement group_id="O4" value="-5.6" spread="7.04"/>
                    <measurement group_id="O5" value="-3.3" spread="5.97"/>
                    <measurement group_id="O6" value="-2.3" spread="6.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in the DLQI Total Score</title>
        <description>DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FASm. Only observed data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in the DLQI Total Score</title>
          <description>DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
          <population>FASm. Only observed data were analyzed.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="5.16"/>
                    <measurement group_id="O2" value="-2.6" spread="4.98"/>
                    <measurement group_id="O3" value="-2.8" spread="4.01"/>
                    <measurement group_id="O4" value="-5.0" spread="5.85"/>
                    <measurement group_id="O5" value="-2.7" spread="4.79"/>
                    <measurement group_id="O6" value="-2.2" spread="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Patient's Global Assessment (PtGA) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12 for Participants With a PtGA Score ≥2 at Baseline</title>
        <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>FASm. Only observed data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Patient's Global Assessment (PtGA) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12 for Participants With a PtGA Score ≥2 at Baseline</title>
          <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).</description>
          <population>FASm. Only observed data were analyzed.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="62"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="17.5"/>
                    <measurement group_id="O3" value="7.3"/>
                    <measurement group_id="O4" value="13.2"/>
                    <measurement group_id="O5" value="14.5"/>
                    <measurement group_id="O6" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a PtGA Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8 for Participants With a PtGA Score ≥2 at Baseline</title>
        <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).</description>
        <time_frame>Baseline, Week 8</time_frame>
        <population>FASm. Only observed data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mild/Moderate: Placebo (Vehicle) BID</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Mild/Moderate: Placebo (Vehicle) QD</title>
            <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a PtGA Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8 for Participants With a PtGA Score ≥2 at Baseline</title>
          <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).</description>
          <population>FASm. Only observed data were analyzed.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="67"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="6.3"/>
                    <measurement group_id="O3" value="10.9"/>
                    <measurement group_id="O4" value="10.0"/>
                    <measurement group_id="O5" value="6.0"/>
                    <measurement group_id="O6" value="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs were assessed from informed consent through and including 28 calendar days after last administration of study treatment. Non-SAEs were recorded from time of first dose of study treatment through last participant visit.</time_frame>
      <desc>The same event may appear as both an AE and an SAE. However, what is presented are distinct events. An event may be categorized as serious in 1 participant and as nonserious in another participant, or 1 participant may have experienced both a serious and nonserious event during the study. All AEs (including treatment area AEs) are presented.</desc>
      <group_list>
        <group group_id="E1">
          <title>Mild/Moderate: Tofacitinib 20 mg/g BID</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Mild/Moderate: Tofacitinib 10 mg/g BID</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Mild/Moderate: Placebo (Vehicle) BID</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), BID for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Mild/Moderate: Tofacitinib 20 mg/g QD</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Mild/Moderate: Tofacitinib 10 mg/g QD</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Mild/Moderate: Placebo (Vehicle) QD</title>
          <description>Participants with a baseline PGA-C score of mild (2) or moderate (3) applied placebo ointment (vehicle), QD for 12 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Severe: Tofacitinib 20 mg/g BID</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 20 mg/g, BID for 12 weeks.</description>
        </group>
        <group group_id="E8">
          <title>Severe: Tofacitinib 10 mg/g BID</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 10 mg/g, BID for 12 weeks.</description>
        </group>
        <group group_id="E9">
          <title>Severe: Placebo (Vehicle) BID</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied placebo ointment (vehicle), BID for 12 weeks.</description>
        </group>
        <group group_id="E10">
          <title>Severe: Tofacitinib 20 mg/g QD</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment, 20 mg/g, QD for 12 weeks.</description>
        </group>
        <group group_id="E11">
          <title>Severe: Tofacitinib 10 mg/g QD</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied tofacitinib ointment 10 mg/g, QD for 12 weeks.</description>
        </group>
        <group group_id="E12">
          <title>Severe: Placebo (Vehicle) QD</title>
          <description>Participants with a baseline PGA-C score of severe (4) applied placebo ointment (vehicle), QD for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Application site papules</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cystitis escherichia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident at work</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Burns first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Drug dispensing error</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Eosinophil percentage increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vitamin B12 decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Catarrh</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Paranasal sinus discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nail psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The PI must remove any previously undisclosed Confidential Information (other than the Study results themselves) before public release.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Efficacy results for participants in the severe population were not reported since this was considered an exploratory population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

